[go: up one dir, main page]

FR3092754B1 - Composition adjuvante pour vaccin - Google Patents

Composition adjuvante pour vaccin Download PDF

Info

Publication number
FR3092754B1
FR3092754B1 FR1901614A FR1901614A FR3092754B1 FR 3092754 B1 FR3092754 B1 FR 3092754B1 FR 1901614 A FR1901614 A FR 1901614A FR 1901614 A FR1901614 A FR 1901614A FR 3092754 B1 FR3092754 B1 FR 3092754B1
Authority
FR
France
Prior art keywords
vaccine
adjuvant composition
relates
present
isoparaffins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1901614A
Other languages
English (en)
Other versions
FR3092754A1 (fr
Inventor
Benjamin Swoboda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TotalEnergies Onetech SAS
Original Assignee
Total Marketing Services SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1901614A priority Critical patent/FR3092754B1/fr
Application filed by Total Marketing Services SA filed Critical Total Marketing Services SA
Priority to EP20710220.3A priority patent/EP3927373A1/fr
Priority to US17/430,554 priority patent/US20220125918A1/en
Priority to MX2021009718A priority patent/MX2021009718A/es
Priority to PCT/FR2020/050267 priority patent/WO2020169903A1/fr
Priority to BR112021015900-2A priority patent/BR112021015900A2/pt
Priority to CN202080013930.4A priority patent/CN113423424A/zh
Publication of FR3092754A1 publication Critical patent/FR3092754A1/fr
Application granted granted Critical
Publication of FR3092754B1 publication Critical patent/FR3092754B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition adjuvante pour vaccin comprenant une ou plusieurs huiles hydrocarbonées essentiellement isoparaffiniques comprenant des isoparaffines en C17 et/ou en C18, et un ou plusieurs tensioactifs. La présente invention concerne également un vaccin comprenant ladite composition adjuvante.
FR1901614A 2019-02-18 2019-02-18 Composition adjuvante pour vaccin Active FR3092754B1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
FR1901614A FR3092754B1 (fr) 2019-02-18 2019-02-18 Composition adjuvante pour vaccin
US17/430,554 US20220125918A1 (en) 2019-02-18 2020-02-13 Adjuvant composition for a vaccine
MX2021009718A MX2021009718A (es) 2019-02-18 2020-02-13 Composicion de adyuvante para una vacuna.
PCT/FR2020/050267 WO2020169903A1 (fr) 2019-02-18 2020-02-13 Composition adjuvante pour vaccin
EP20710220.3A EP3927373A1 (fr) 2019-02-18 2020-02-13 Composition adjuvante pour vaccin
BR112021015900-2A BR112021015900A2 (pt) 2019-02-18 2020-02-13 Vacina, composição de adjuvante para uma vacina e seu uso
CN202080013930.4A CN113423424A (zh) 2019-02-18 2020-02-13 用于疫苗的佐剂组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1901614 2019-02-18
FR1901614A FR3092754B1 (fr) 2019-02-18 2019-02-18 Composition adjuvante pour vaccin

Publications (2)

Publication Number Publication Date
FR3092754A1 FR3092754A1 (fr) 2020-08-21
FR3092754B1 true FR3092754B1 (fr) 2022-06-03

Family

ID=67002015

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1901614A Active FR3092754B1 (fr) 2019-02-18 2019-02-18 Composition adjuvante pour vaccin

Country Status (7)

Country Link
US (1) US20220125918A1 (fr)
EP (1) EP3927373A1 (fr)
CN (1) CN113423424A (fr)
BR (1) BR112021015900A2 (fr)
FR (1) FR3092754B1 (fr)
MX (1) MX2021009718A (fr)
WO (1) WO2020169903A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112213438A (zh) * 2020-10-12 2021-01-12 青岛易邦生物工程有限公司 一种灭活疫苗佐剂白油检验方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3817531A1 (de) * 1988-05-24 1989-12-07 Behringwerke Ag Antigenloesung enthaltend ein polyalphaolefin (pao), verfahren ihrer herstellung und die verwendung von pao als adjuvans
RU2072868C1 (ru) * 1991-12-18 1997-02-10 Шабалина Татьяна Николаевна Состав для приготовления биопрепаратов
FR2703247B1 (fr) * 1993-03-29 1995-06-09 Oreal Emulsion a base de dihydroxyacetone et son utilisation en cosmetique.
US7691368B2 (en) * 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US20060264684A1 (en) 2005-05-19 2006-11-23 Petri John A Production of diesel fuel from biorenewable feedstocks
FR2922767B1 (fr) 2007-10-24 2009-12-18 Seppic Sa Procede de preparation d'une composition vaccinale comprenant au moins un antigene et au moins un adjuvant.
ITMI20121465A1 (it) 2012-09-03 2014-03-04 Eni Spa Metodo per convertire una raffineria convenzionale di oli minerali in una bioraffineria
EP3095839A1 (fr) * 2015-05-20 2016-11-23 Total Marketing Services Procédé pour la production de fluides hydrocarbonés biodégradables par hydrogénation
EP3095838A1 (fr) 2015-05-20 2016-11-23 Total Marketing Services Procédé pour la production de fluides hydrocarbonés biodégradables
EP3143981A1 (fr) * 2015-09-16 2017-03-22 Total Marketing Services Composition émolliente biosourcée

Also Published As

Publication number Publication date
WO2020169903A1 (fr) 2020-08-27
BR112021015900A2 (pt) 2021-10-05
MX2021009718A (es) 2021-12-10
FR3092754A1 (fr) 2020-08-21
CN113423424A (zh) 2021-09-21
EP3927373A1 (fr) 2021-12-29
US20220125918A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
MA40061A (fr) Compositions immunogènes à base de listeria pour provoquer des réponses anti-tumorales
MA44322A (fr) Compositions comprenant des souches bactériennes
MA40306A1 (fr) Méthodes et formulations pour le traitement de pathologies oculaires vasculaires
EA200901270A1 (ru) Стимуляция иммунной реакции катионными липидами
MA42471B1 (fr) Compositions comprenant des souches bactériennes
CR9428A (es) Metodos para el tratamiento y la prevencion de fibrosis
MA44890A (fr) Compositions comprenant des souches bactériennes
EA202092586A1 (ru) Ингибиторы magl
MA41887A1 (fr) Dérivé de glucagon et composition comprenant un conjugué à action prolongée de celui-ci
MA30866B1 (fr) Vaccin
ECSP045098A (es) Procedimientos para tratar enfermedades neovasculares oculares
TN2018000341A1 (en) ANTl-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF.
BR112018075653A2 (pt) anticorpos anti-b7-h3 e conjugados anticorpo fármaco
DK1830881T3 (da) Kombinationsterapier, som er målrettet mod multiple toll-like-receptorer og anvendelse deraf
MA39909B1 (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
EA202090312A1 (ru) Спироциклические соединения и способы их получения и применения
EA201992409A1 (ru) Ингибиторы magl на основе пиразола
EA202192786A1 (ru) Твердые формы (e)-3-[2-(2-тиенил)винил]-1h-пиразола
FR3092754B1 (fr) Composition adjuvante pour vaccin
MA46988A1 (fr) Formulation liquide d'anticorps anti-tnf alpha
MA34709B1 (fr) Compositions pharmaceutiques
EA202191610A1 (ru) Композиции, полученные из сконструированного флагеллина, и их применение
FR3073142B1 (fr) Formulation cosmetique
WO2002056010A3 (fr) Methodes destinees au traitement du syndrome du colon irritable (ibs)

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20200821

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

TP Transmission of property

Owner name: TOTALENERGIES ONETECH, FR

Effective date: 20230309

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7